Rosuvastatin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026


#5993

Transparency Market Research

$ 5795

Rosuvastatin (available under the brand name “Crestor”) belongs to a type of drug called “statins”. Along with proper diet and exercise, Rosuvastatin can be used to reduce bad cholesterol and fats (LDL, triglycerdies, etc.) and increase the level of good cholesterol in the blood. Raising the level of good cholesterol and lowering the level of bad cholesterol in blood helps reduce the risk of heart diseases, stroke, and other types of cardiovascular abnormalities. Although Rosuvastatin does not have any major side effect, it may sometimes show minor health abnormalities, such as, muscle pain, weakness, diabetes, nausea, vomiting, trouble in breathing etc. Therefore, before taking Rosuvastatin drugs, patients are recommended to consult a doctor.

The global Rosuvastatin market is primarily driven by growing population across the world, increasing prevalence of obesity and awareness about the negative outcomes of obesity, and developing health care infrastructure. However, stringent regulatory conditions and intellectual property rights are likely to restrain the growth of the global Rosuvastatin market during the forecast period. Nevertheless, availability of generic products, competition among brand and generic companies, and increasing R&D investments are projected to create growth opportunities for the global Rosuvastatin market in the near future.

In terms of application. the global Rosuvastatin market can be segmented based on treatment of obesity, treatment of stroke, treatment in pancreatitis, and others, The treatment of obesity segment constituted the leading share of the Rosuvastatin market in 2017. The segment is expected to retain its dominance during the forecast period. Based on mode of delivery, the global Rosuvastatin market can be classified into oral, parenteral, and others. The oral segment accounted for the maximum share of the Rosuvastatin market in 2017. It is anticipated to expand at a significant CAGR during the forecast period. By distribution channel, the global Rosuvastatin market can be categorized into hospital pharmacies, retail pharmacies and drug stores, and others. The others segment includes online sales. It is expected to growth at a significant rate during the forecast period. 

Geographically, the global Rosuvastatin market can be classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Prevalence of obesity in North America was estimated at 39.8% in 2017, whereas, that in Canada was estimated at 20% in the same year. The Rosuvastatin market in North America held the leading market share in 2017, owing to growth in population, significant prevalence of obesity, preference of non-surgical treatment, rise in awareness regarding health care, and robust health care infrastructure in the region. The U.K. has the highest number of obese people in Europe, followed by France, German, Poland, and others. The Rosuvastatin market in Europe accounted for the second leading market share in 2017. It is anticipated to expand at a significant growth rate during the forecast period due to increase in prevalence of obesity and high preference of non-surgical treatment in the region, along with rise in health care awareness in Western Europe. The Rosuvastatin market in Asia Pacific constituted the next leading market share in 2017. It is anticipated to expand at a significant growth rate during the forecast period due to large patient population pool, developing medical infrastructure, availability of generic companies, and competition between key market players and generic companies in the region. However, lack of medical awareness and weak medical infrastructure are likely to hamper the growth of the Rosuvastatin market in Latin America and Middle East & Africa during the forecast period.  

Key companies operating in the global Rosuvastatin market include IPR Pharmaceuticals Inc, Watson Labs Inc., Torrent Pharms Ltd., Teva Pharmaceutical, Sun Pharma, Sandoz (parent company - Novartis), Lupin, Hetero Labs, Biocon, Cadilla Pharma, Aurobindo Pharma, and Apotex Inc.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.